{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T17:56:28Z","timestamp":1776448588057,"version":"3.51.2"},"reference-count":38,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Clinics of North America"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.ucl.2026.02.007","type":"journal-article","created":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T12:24:20Z","timestamp":1773491060000},"page":"243-252","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Managing Clinical N1 Prostate Cancer"],"prefix":"10.1016","volume":"53","author":[{"given":"Saeed","family":"Imam","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bertram","family":"Yuh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.ucl.2026.02.007_bib1","doi-asserted-by":"crossref","first-page":"3176","DOI":"10.21037\/tau-20-1031","article-title":"Narrative review of management strategies and outcomes in node-positive prostate cancer","volume":"10","author":"D\u2019Rummo","year":"2021","journal-title":"Transl Androl Urol"},{"issue":"3","key":"10.1016\/j.ucl.2026.02.007_bib2","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.euo.2019.02.001","article-title":"A systematic review of the role of definitive local treatment in patients with clinically lymph node-positive prostate cancer","volume":"2","author":"Ventimiglia","year":"2019","journal-title":"Eur Urol Oncol"},{"issue":"1","key":"10.1016\/j.ucl.2026.02.007_bib3","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J Clin"},{"issue":"10231","key":"10.1016\/j.ucl.2026.02.007_bib4","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","article-title":"Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent treatment (proPSMA)","volume":"395","author":"Hofman","year":"2020","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.ucl.2026.02.007_bib5","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.eururo.2016.06.021","article-title":"Sensitivity, specificity, and predictors of positive 68Ga\u2013PSMA PET scans in advanced prostate cancer: a systematic review and meta-analysis","volume":"70","author":"Perera","year":"2016","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.ucl.2026.02.007_bib6","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s40644-024-00742-3","article-title":"Pelvic lymph node mapping in prostate cancer: impact of PSMA PET\/CT on radiotherapy planning","volume":"24","author":"Michaeli","year":"2024","journal-title":"Cancer Imaging"},{"issue":"11","key":"10.1016\/j.ucl.2026.02.007_bib7","first-page":"1689","article-title":"Imaging evaluation of prostate cancer with 18F-FDG PET\/CT: utility and limitations","volume":"52","author":"Jadvar","year":"2011","journal-title":"J Nucl Med"},{"issue":"4","key":"10.1016\/j.ucl.2026.02.007_bib8","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.crad.2007.05.022","article-title":"The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis","volume":"63","author":"H\u00f6vels","year":"2008","journal-title":"Clin Radiol"},{"issue":"2","key":"10.1016\/j.ucl.2026.02.007_bib9","first-page":"W201","article-title":"Diffusion-weighted MRI for discriminating malignant from benign lymph nodes in patients with prostate cancer","volume":"197","author":"Tamada","year":"2011","journal-title":"AJR Am J Roentgenol"},{"issue":"25","key":"10.1016\/j.ucl.2026.02.007_bib10","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1056\/NEJMoa022749","article-title":"Noninvasive detection of clinically occult lymph-node metastases in prostate cancer","volume":"348","author":"Harisinghani","year":"2003","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ucl.2026.02.007_bib11","first-page":"743","article-title":"Localized prostate cancer detection with 18F fluciclovine PET\/CT: histopathologic correlation","volume":"283","author":"Turkbey","year":"2017","journal-title":"Radiology"},{"issue":"6","key":"10.1016\/j.ucl.2026.02.007_bib12","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.eururo.2012.09.039","article-title":"Utility of choline PET\/CT for lymph node involvement in intermediate- to high-risk prostate cancer: a systematic review and meta-analysis","volume":"63","author":"Evangelista","year":"2013","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.ucl.2026.02.007_bib13","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.euo.2023.09.002","article-title":"Local therapy on clinically lymph node\u2013positive prostate cancer: a systematic review and meta-analysis","volume":"7","author":"Yaow","year":"2024","journal-title":"Eur Urol Oncol"},{"issue":"10162","key":"10.1016\/j.ucl.2026.02.007_bib14","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1016\/S0140-6736(18)32486-3","article-title":"Radiotherapy to the primary tumour for newly diagnosed metastatic prostate cancer (STAMPEDE trial)","volume":"392","author":"Parker","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.ucl.2026.02.007_bib15","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.859785","article-title":"Overcoming immune resistance with radiation therapy in prostate cancer","volume":"13","author":"Mulvey","year":"2022","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.ucl.2026.02.007_bib16","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.eururo.2014.09.006","article-title":"Tracking the origin of metastatic prostate cancer","volume":"67","author":"Lindberg","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.ucl.2026.02.007_bib17","doi-asserted-by":"crossref","first-page":"90","DOI":"10.3389\/fonc.2015.00090","article-title":"Neuroendocrine differentiation in prostate cancer: a mechanism of radioresistance and treatment failure","volume":"5","author":"Hu","year":"2015","journal-title":"Front Oncol"},{"issue":"9660","key":"10.1016\/j.ucl.2026.02.007_bib18","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0140-6736(08)61815-2","article-title":"Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7\/SFUO-3)","volume":"373","author":"Widmark","year":"2009","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.ucl.2026.02.007_bib19","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1200\/JCO.2014.57.7510","article-title":"Final report of the intergroup randomized study of androgen deprivation therapy with or without radiotherapy in locally advanced prostate cancer","volume":"33","author":"Mason","year":"2015","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ucl.2026.02.007_bib20","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1200\/JCO.2005.08.141","article-title":"Androgen suppression plus radiotherapy versus radiotherapy alone for node-positive prostate cancer: updated results of RTOG 85-31","volume":"23","author":"Lawton","year":"2005","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ucl.2026.02.007_bib21","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.juro.2006.03.092","article-title":"Long-term follow-up of a randomized study of orchiectomy and radiotherapy vs radiotherapy alone in locally advanced prostate cancer with or without pelvic node involvement","volume":"176","author":"Granfors","year":"2006","journal-title":"J Urol"},{"issue":"24","key":"10.1016\/j.ucl.2026.02.007_bib22","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1056\/NEJMoa0810095","article-title":"Duration of androgen suppression in the treatment of prostate cancer","volume":"360","author":"Bolla","year":"2009","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.ucl.2026.02.007_bib23","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1002\/phar.2168","article-title":"Risks of major long-term side effects associated with androgen-deprivation therapy in men with prostate cancer","volume":"38","author":"Nguyen","year":"2018","journal-title":"Pharmacotherapy"},{"issue":"2","key":"10.1016\/j.ucl.2026.02.007_bib24","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0090-4295(01)01168-2","article-title":"Addition of radiation therapy to androgen ablation improves outcome for subclinically node-positive prostate cancer","volume":"58","author":"Zagars","year":"2001","journal-title":"Urology"},{"issue":"5","key":"10.1016\/j.ucl.2026.02.007_bib25","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.ijrobp.2014.01.008","article-title":"The impact of definitive local therapy for lymph node-positive prostate cancer: a population-based study","volume":"88","author":"Rusthoven","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"10.1016\/j.ucl.2026.02.007_bib26","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.eururo.2017.08.011","article-title":"Efficacy of local treatment in prostate cancer patients with clinically pelvic lymph node-positive disease at initial diagnosis","volume":"73","author":"Seisen","year":"2018","journal-title":"Eur Urol"},{"issue":"10162","key":"10.1016\/j.ucl.2026.02.007_bib27","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1016\/S0140-6736(18)32486-3","article-title":"Radiotherapy to the primary tumour for newly diagnosed metastatic prostate cancer (STAMPEDE)","volume":"392","author":"Parker","year":"2018","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.ucl.2026.02.007_bib28","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/S1470-2045(06)70700-8","article-title":"Immediate vs deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy","volume":"7","author":"Messing","year":"2006","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.ucl.2026.02.007_bib29","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.eururo.2008.09.008","article-title":"Early vs delayed endocrine treatment of pN1\u20133 M0 prostate cancer without local treatment of the primary tumor: final results of EORTC 30846 after 13 years of follow-up","volume":"55","author":"Schr\u00f6der","year":"2009","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.ucl.2026.02.007_bib30","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.eururo.2017.09.027","article-title":"Survival outcomes of men with lymph node-positive prostate cancer after radical prostatectomy: a comparative analysis of different post-operative management strategies","volume":"73","author":"Touijer","year":"2018","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.ucl.2026.02.007_bib31","first-page":"912","article-title":"Long-term oncologic outcomes of observation in node-positive prostate cancer after radical prostatectomy","volume":"195","author":"Gupta","year":"2016","journal-title":"J Urol"},{"issue":"3","key":"10.1016\/j.ucl.2026.02.007_bib32","first-page":"456","article-title":"Patterns of care and outcomes of patients with positive lymph nodes after radical prostatectomy: a population-based study","volume":"23","author":"Preisser","year":"2020","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"6","key":"10.1016\/j.ucl.2026.02.007_bib33","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.eururo.2018.10.042","article-title":"Long-term outcomes of patients with clinically node-positive prostate cancer treated with radical prostatectomy: impact of nodal burden on survival","volume":"75","author":"Gandaglia","year":"2019","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.ucl.2026.02.007_bib34","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.juro.2017.01.063","article-title":"Impact of radical prostatectomy on long-term cancer control in men with pN1 prostate cancer managed by immediate ADT","volume":"198","author":"Bhindi","year":"2017","journal-title":"J Urol"},{"issue":"2","key":"10.1016\/j.ucl.2026.02.007_bib35","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.eururo.2014.05.011","article-title":"More extensive pelvic lymph node dissection improves survival in patients with node-positive prostate cancer","volume":"67","author":"Abdollah","year":"2015","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.ucl.2026.02.007_bib36","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.eururo.2011.02.024","article-title":"Combination of adjuvant hormonal and radiation therapy in pT2-4 pN+ prostate cancer significantly improves survival: a matched analysis","volume":"59","author":"Briganti","year":"2011","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.ucl.2026.02.007_bib37","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.eururo.2009.01.046","article-title":"Long-term follow-up of patients with prostate cancer and nodal metastases treated by radical prostatectomy and pelvic lymphadenectomy: positive impact of adjuvant radiotherapy","volume":"55","author":"Da Pozzo","year":"2009","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.ucl.2026.02.007_bib38","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.eururo.2018.04.017","article-title":"Impact of adjuvant radiotherapy on survival of patients with node-positive prostate cancer: the importance of patient selection","volume":"74","author":"Abdollah","year":"2018","journal-title":"Eur Urol"}],"container-title":["Urologic Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0094014326000078?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0094014326000078?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T17:20:41Z","timestamp":1776446441000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0094014326000078"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S0094014326000078"],"URL":"https:\/\/doi.org\/10.1016\/j.ucl.2026.02.007","relation":{},"ISSN":["0094-0143"],"issn-type":[{"value":"0094-0143","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Managing Clinical N1 Prostate Cancer","name":"articletitle","label":"Article Title"},{"value":"Urologic Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ucl.2026.02.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}